Original Research Article

A study on peripheral neuropathy in HIV infected patients: clinicoepidemiological and electrophysiological profile

K. Gunasekaran*, S. Sivakumar

Department of Neurology, Government Mohan Kumaramangalam Medical College Hospital, Salem, Tamilnadu, India

Received: 27 August 2018
Accepted: 18 September 2018

*Correspondence:
Dr. K. Gunasekaran,
E-mail: drgunasekaranneuro@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: Peripheral neuropathy is one among the commonest HIV-associated neurologic complications. The spectrum and the frequency of this complication are changing due to the introduction of new antiretroviral drugs, aging of the HIV-infected people, etc. Hence there is need for a better understanding of these complications and their pathogenesis. This study was done with the aim of finding out the risk factors, clinical characteristics and various types and patterns of peripheral neuropathy in HIV infected patients of our region.

Methods: This study was a cross sectional study conducted for about a period of one year. Patients attending the outpatient department of anti retroviral therapy (ART) centre were taken for the study. Selected patients were analysed for the signs and symptoms of peripheral neuropathy and they underwent electrophysiological study.

Results: Prevalence of peripheral neuropathy in HIV infected patients in our study population was 43.3%. Peripheral neuropathy was seen more in patients with advanced clinical stage and increasing age. Distal symmetric polyneuropathy was the commonest type. Common pathological pattern of neuropathy was mixed (both axonal and demyelination) neuropathy.

Conclusions: As peripheral neuropathy is a common HIV-associated neurologic complication, large number of studies are needed to elucidate the mechanisms leading to peripheral neuropathy in HIV infected patients, which in turn will allow for the development of effective therapies that provide adequate symptomatic relief and halt or reverse the damage to the nerves.

Keywords: Distal symmetric polyneuropathy, Electrophysiology, HAART, HIV infection, Peripheral neuropathy

INTRODUCTION

The life expectancy of human immunodeficiency virus (HIV) infected patients is increasing nowadays as a result of highly active antiretroviral therapy (HAART). Consequently, treating physicians need to deal with neurologic complications from the HIV disease, from concurrent diseases, and from drugs used to treat them. Peripheral neuropathy is one among the commonest HIV-associated neurologic complications. The spectrum and the frequency of this complication are changing due to the introduction of new antiretroviral drugs, aging of the HIV-infected people, and the emergence of other long-term complications of HIV and its treatment. Several forms of neuropathy may occur, depending on the level of immunosuppression and the presence of risk factors. Hence, there is a great need for a better understanding of these complications and their pathogenetic mechanisms, for the development of effective therapies that provide sufficient symptomatic relief and halt or reverse the damage to the nerves.
Aims of the study was to study the prevalence of peripheral neuropathy in HIV infected patients. Also, to find out the risk factors associated with the development of peripheral neuropathy and to study the clinical profile and various types and patterns of peripheral neuropathy in HIV infected patients.

METHODS

This study was a cross sectional study, conducted during the period of January 2009 to December 2009, for about 1 year at Department of Neurology, Tirunelveli Medical college Hospital, Tirunelveli, southern part of Tamilnadu state.

Patient selection

Patients attending the out patient department of anti-retroviral therapy (ART) Centre of our institute were taken for the study. Patients already diagnosed as HIV positive and on highly active anti-retroviral therapy (HAART) only were selected. Both male and female patients were taken. Study was done with the consent of the patients as well as with the institution’s ethical committee approval.

Inclusion criteria

- Patients who were seropositive for HIV infection and registered with ART Centre.
- Patients on HAART.
- Both symptomatic and asymptomatic patients, irrespective of stage of the disease, CD4 count and duration of the HIV illness.

Exclusion criteria

- HIV seropositive patients who were not on HAART at the time of the study.
- Patients with other systemic illness like diabetes mellitus, renal disease, thyroid disease, nutritional anaemia, Hansen’s disease.
- History suggestive of collagen vascular diseases, recent Chikungunya fever or any other viral illness or jaundice.
- Patients who regularly consume alcohol of > 40 units/week.

All the patients were analysed for symptoms and signs of peripheral neuropathy and biochemical investigations and complete hemogram were done to rule out other systemic illness.

Electrophysiological study

All the patients were encouraged to undergo nerve conduction study (NCS). But only in 30 patients NCS could be done. Sensory nerve conduction studies of the sural, ulnar and median nerves were performed orthodromically. For motor nerve conduction studies, supramaximal nerve stimulation was applied transcutaneously to a distal and proximal segment of the tibial, peroneal, median and ulnar nerves. F-wave latencies were obtained from the median, ulnar, peroneal and tibial motor nerves. Electrophysiological diagnosis of peripheral neuropathy was done with standard reference values.6

RESULTS

Data of total study population

Epidemiological data

Total number of patients in our study group was 60. Among them males were 33 (55%) and females were 27 (45%). Patients were in varying age groups, minimum of 21 years to maximum of 54 years. Males were aged from 28 to 54 years and females were from 21 to 52 years. Among the total number of 60 patients, 23 (38.3%) patients had symptoms of peripheral neuropathy and remaining were asymptomatic.

Clinical data

Patients were staged according to WHO staging system.7 More number of patients were in stages III and IV (65%) compared to stages I and II (35%). (Chi-square: 18.750; df: 3, p-value <0.0001) (Figure 1).

![Figure 1: Clinical stage and sex distribution of study population.](image)

The duration of HAART varied from 1-48 months with mean of 23 months. Those who were on HAART of <12 months were 20, 13-24 months were 19, in 25-36 months were 12, >37 months were 9. (Chi-square: 3.015, p-value = 0.398). CD4 count was done twice in ART clinic. One at time of diagnosis of HIV seropositivity and another one done recently, that is while undergoing this study. Patients having CD4 <200 are 31 (51.7%) >200 are 29 (48.3%). Patients were on various regimen. In the ART centre, 4 types of regimens were followed, which contain...
2 NRTIs and 1 NNRTI. The following regimens are used: ZLN, ZLE, SLN, SLE. Among NRTIs lamivudine was compulsorily added and either zidovudine (if no anemia) or stavudine (if no PN) was added. Among NNRTIs either nevirapine (if no ATT or hepatotoxicity) or efavirenz (if nevirapine contraindicated) was used. Some patients who were suffering from pulmonary tuberculosis (PT) were started on ATT (anti-tuberculosis treatment) first and then after completing ATT, later started on HAART and in between also if PT was detected, HAART stopped and ATT started and HAART restarted later. Totally 23 such patients were given ATT at one point of time. Among whom one was presently on ATT at the time of our study. The following table shows the various treatment regimen patients were on (Table 1).

Table 1: Various treatment regimens of the total study population.

| Regimen       | Frequency | Percentage |
|---------------|-----------|------------|
| On ATT        | 1         | 1.7        |
| SLE ATT       | 1         | 1.7        |
| SLE SLN       | 1         | 1.7        |
| SLE ZLN       | 1         | 1.7        |
| SLN           | 12        | 20.0       |
| SLN SLN       | 1         | 1.7        |
| SLN ZLN       | 8         | 13.3       |
| ZLE SLN       | 1         | 1.7        |
| ZLN SLN       | 1         | 1.7        |
| ZLE           | 1         | 1.7        |
| ZLE ATT       | 1         | 1.7        |
| ZLE ZLN       | 8         | 13.3       |
| ZLN           | 15        | 25.0       |
| Total         | 60        | 100.0      |

(Z-zidovudine, L-lamivudine, S-stavudine, N-nevirapine, E-efavirenz, ATT-Antituberculosis Treatment)

Data of peripheral neuropathy group

Among the study group of 60 patients, 26 were having evidence of peripheral neuropathy (Figure 2). Different topographical and clinical types of peripheral neuropathy were noticed (Figure 3). These patients were in different age groups as follows (Table 2).

In the total study group, 39/60 were in stages III and IV and 21/60 were in stages I and II. Among the 39 patients of stage III and IV, 19 (48.7%) had peripheral neuropathy and among the 21 patients of stage I and II, 7 had peripheral neuropathy (Table 3).

Duration of HAART

Among the 39 patients of less than 24 months duration of HAART, 18 (46.2%) suffered from peripheral neuropathy and among the 21 patients of more than 24 months duration of HAART, 8 (38.1%) suffered from peripheral neuropathy. (Chi-square: 3.825, p-value = 0.281) (Figure 4).

Figure 2: Peripheral neuropathy prevalence.

![Peripheral neuropathy prevalence](image)

Figure 3: Sex and peripheral neuropathy types.

![Sex and peripheral neuropathy types](image)

Table 2: Number of patients with peripheral neuropathy in various age groups.

| Age group (Yrs) | Total | Peripheral Neuropathy present | peripheral neuropathy absent | % of peripheral neuropathy |
|----------------|-------|-------------------------------|-----------------------------|---------------------------|
| 21-30          | 13    | 5 (19.2%)                     | 8 (23.5%)                   | 38.5 %                    |
| 31-40          | 33    | 13 (50.0%)                    | 20 (58.8%)                  | 39.4 %                    |
| 41-50          | 11    | 5 (19.2%)                     | 6 (17.6%)                   | 45.5 %                    |
| Above 51       | 3     | 3 (11.5%)                     | 0 (0.0%)                    | 100 %                     |
| Total          | 60    | 26                            | 34                           |                           |

Chi-square: 4.277, p-value: 0.233

CD4 count

Those patients with peripheral neuropathy with CD4 <200 were 9 (34.6%), and >200 were 17 (65.4%). In total study group, patients with CD4 <200 were 31 (51.7%) and >200 were 29 (48.3%).

Treatment regimen

When correlating the duration of HAART with type of regimen and peripheral neuropathy, it shows the...
following results: (Figure 5) (Table 4). Distribution of symptoms and signs were as mentioned (Figure 6).

Table 3: Number of patients with peripheral neuropathy in various clinical stages.

| Stage | Peripheral Neuropathy – Present | Peripheral Neuropathy - Absent | Total |
|-------|---------------------------------|--------------------------------|-------|
| I     | 6 (23.1%)                       | 13 (38.2%)                     | 19 (31.7%) |
| II    | 1 (3.0%)                        | 1 (2.9%)                       | 2 (3.3%)  |
| III   | 15 (55.7%)                      | 17 (50.0%)                     | 32 (53.3%)|
| IV    | 4 (15.4%)                       | 3 (8.8%)                       | 7 (11.7%) |
| Total | 26                              | 34                             | 60 (100%)|

Chi-square: 1.812, p-value: 0.612.

Table 4: Duration of HAART and type of regimen in relation to peripheral neuropathy.

| Duration of HAART | Total no. patients | Stavudine users (A) | Peripheral neuropathy present in (A) | Non-stavudine users (B) | Peripheral neuropathy present in (B) |
|-------------------|--------------------|---------------------|--------------------------------------|-------------------------|-------------------------------------|
| 0-12 months       | 20                 | 10                  | 5 (50%)                              | 10                      | 7 (70%)                             |
| 13-24 months      | 19                 | 10                  | 4 (40%)                              | 9                       | 2 (22.2%)                           |
| 25-36 months      | 12                 | 8                   | 3 (37.5%)                            | 4                       | 1 (25%)                             |
| > 36 months       | 9                  | 6                   | 4 (66.7%)                            | 3                       | Nil                                 |
| Total             | 60                 | 34                  | 16 (47.1%)                           | 26                      | 10 (38.5%)                          |

Patients, who didn’t have either symptoms or signs of peripheral neuropathy, were 35. Among them 5 underwent electrophysiological analysis. One of them showed electrophysiological evidence of peripheral neuropathy. All the symptomatic patients had electrophysiological evidence of peripheral neuropathy and this is statistically significant as p-value was <0.0001.

Symptoms and signs

Symptoms were numbness (17 patients), tingling (8 patients), electric shock-like sensation (5 patients), burning pain (3 patients), pins and needles sensation (5 patients), cramps (4 patients) and weakness (2 patients). Most of the patients showed symptoms in lower limbs.
(20 patients). Only in 5 patients symptoms were present in both upper and lower limbs.

Sensory signs were diminished vibration, touch, pain and temperature in that order. In 17 patients all modalities like vibration, touch, pain and temperature were lost in lower limbs. In 8 patients, only vibration impairment was seen. In 3 patients sensory signs (impairment of vibration) were present in hands. Ankle jerk was diminished in 6 patients and absent in 11 patients. 4 patients had diminished knee jerk. Weakness in ankle dorsiflexion and plantar flexion were seen in 2 patients, weakness in extension of great toe was present in 4 patients and in 7 patients toe-grip was weak. Wasting seen in intrinsic foot muscles in 3 patients. In upper limbs, signs were not seen except in patients with CIDP (Chronic Inflammatory Demyelinating Polyneuropathy) who showed both sensory and motor features. Likewise CIDP patients had both proximal and distal weakness in lower limbs.

Electrophysiology

Nerve conduction study was done totally in 30 patients. Among them, electrophysiological evidence of peripheral neuropathy was seen in 26 patients. Predominant pattern seen was mixed neuropathy (both axonal and demyelination) in 18 patients. Among the 5 patients with CIDP, 1 patient had features of both axonal and demyelination pattern and others had predominant demyelination pattern. 3 patients had only axonal pattern. Both motor and sensory neuropathy were seen in 24 patients and only sensory neuropathy was seen in 2 patients.

DISCUSSION

In this study, a survey of variables related to peripheral nerve function was done in the group of HIV-infected individuals. Also nerve conduction studies and several potential pathogenetic factors have been systematically studied. Among the 60 patients under the study, 26 patients were having peripheral neuropathy and electrophysiological study confirmed this.

Types of peripheral neuropathy

Among the 26 patients with peripheral neuropathy, distal symmetrical polyneuropathy (DSP) was the commonest (69.2%) type. Other types seen were distal symmetric polyneuropathy with only sensory findings (Distal Sensory Polyneuropathy) (7.7%), CIDP (19.2%) and Mononeuritis Multiplex (MM) (3.8%). Among the inflammatory demyelinating polyneuropathies, both AIDP (acute inflammatory demyelinating polyradiculoneuropathy) and CIDP (chronic inflammatory demyelinating polyradiculoneuropathy) can occur in HIV infected patients.8 Acute form often presents at the time of HIV seroconversion or primary infection. But we did not encounter AIDP though we had 5 patients of CIDP. This may be because of the method of patient selection. We selected patients from out patient department of ART centre where they come for follow up and getting drugs. Other types described in text books and literature like progressive polyradiculopathy, autonomic neuropathy and mononeuropathy were not seen in our study, as noted in other Indian study.9,10

In our study, distal symmetric polyneuropathy was the commonest type (76.9%), an observation similar to those described in literature.11,13 As this distal symmetric polyneuropathy can occur due to HAART as well as due to ATT, it needs prospective analysis to find out whether it was drug induced.

Age

In our study prevalence gradually increased from 38.5% to 100% as the age advanced, similar to other studies.14 But it is not statistically significant (p-value= 0.233). An article reviewing the impact of aging in HIV infection and its neurological complications explains that aging is associated with a higher viral load and immunosenescence, with a decrease in the naive subsets of CD4 cells, decreases in T cell proliferative responses and decreased ability to respond to novel pathogens, resulting in a potential synergism between HIV infection and aging.15

Duration of HAART

In our study, PN was less in those patients on HAART of longer duration. HAART lessens disease progression, improves immunity, and widens the ratio of therapeutic to toxic effects of individual antiretroviral drugs, resulting in a significantly lower risk of developing peripheral neuropathy.

Treatment regimen

Among the drugs used as HAART, the ‘d’ drugs (didanosine, zalcitabine, stavudine) are prone to produce neurotoxicity. In our ART centre stavudine was used and other 2 drugs were not used. So, patients were divided into those on stavudine (stavudine group) and not on stavudine (non-stavudine group).

Peripheral neuropathy was seen in 47.1% of stavudine users and in 36% of non-stavudine users. This shows more number of peripheral neuropathy in stavudine users, an observation similar to the findings seen in other studies.16

Another observation was that in all the stages of the disease, peripheral neuropathy was slightly more in stavudine users. This suggests the possibility of drug toxicity of the stavudine was an added factor for the development of peripheral neuropathy in all the stages.
Interestingly in less than 12 months duration of HAART, peripheral neuropathy patients on stavudine regimen were 5 and on non-stavudine regimen were 5. That is, at the time of seroconversion, peripheral neuropathy was seen equally in both stavudine and non-stavudine regimen. But when duration of HAART increased, more number of patients were seen in stavudine regimen. This indicates that peripheral neuropathy in the initial period of seroconversion might be due to the disease process itself whereas in peripheral neuropathy of later period, might have been due to drug toxicity, as it was noted mainly in stavudine users. However, this is a study of small group and this needs to be evaluated with large number of patients.

Stage of disease

Increased risk of developing peripheral neuropathy noted in advanced stages (stage III and IV), an observation similar to other studies. But it is not statistically significant in our study (p-value: 0.612).

CD4 count

There was no increased risk of developing peripheral neuropathy for those patients with less CD4 count. Peripheral neuropathy in patients with CD4 count more than 200 suggest that peripheral neuropathy may be due to drug toxicity or other underlying conditions as described in literature.\textsuperscript{17}

### Analysis of symptoms and signs

Frequent symptoms we came across were numbness, tingling, electric shock like sensation with less frequently burning pain, pins and needles. Our findings are comparable with those reported in previous studies, in which subjective pain was uncommon and usually present in more advanced stages.\textsuperscript{18,19} These observations are similar to that reported in some other studies also. Some patients (4) had cramps in both legs, as reported in some other series, which could be due to motor neuropathy or metabolic or drug related and could not be differentiated. Electrophysiological study picked up the presence of peripheral neuropathy even in upper limbs in some patients who had signs only in lower limbs. This indicates the presence of subclinical neuropathy in asymptomatic sites.

Sensory signs seen in our study were diminished vibration, touch, pain and temperature in that order. Predominant motor sign was diminished or absent ankle jerk. Others were diminished knee jerk, weakness in ankle dorsiflexion and plantar flexion, weakness in extension of great toe, toe-grip weakness and wasting in foot intrinsic muscles. Both sensory and motor signs present in our study are similar to what described in literature.

The following table shows the statistical analysis of peripheral neuropathy with various as mentioned factors (Table 5).

| Factor                  | Peripheral neuropathy - present (N= 26) | Peripheral neuropathy - absent (N= 34) | Odds ratio | Chi-square | p-value |
|-------------------------|-----------------------------------------|----------------------------------------|------------|------------|---------|
| Age ≥ 36 years          | 19 (73.1%)                              | 15 (44.1%)                             | 3.48       | 5.032      | 0.025   |
| Sex - male              | 17 (65.4%)                              | 16 (47.1%)                             | 1.37       | 1.999      | 0.157   |
| Duration ≥ 22 months    | 11 (42.3%)                              | 19 (55.9%)                             | 0.58       | 1.086      | 0.297   |
| Symptom of PN           | 23 (88.5%)                              | 0 (0.0%)                               | 21.3       | 48.77      | 0.000   |
| Clinical stage - III and IV | 19 (73.1%)                         | 20 (58.8%)                             | 1.24       | 1.321      | 0.251   |
| Cd4 count ≤ 200         | 12 (46.2%)                              | 19 (55.9%)                             | 0.67       | 0.558      | 0.455   |

The above analysis conclude that increasing age and advanced clinical stages are significantly associated with more prevalence of peripheral neuropathy.

Electrophysiological study

Among the 26 patients with electrophysiological evidence of peripheral neuropathy, 23 had symptoms and 2 had signs. It infers peripheral neuropathy might be seen in patient with either symptoms or signs. Hence detailed history and clinical examination for symptoms and signs of peripheral neuropathy is essential in all HIV infected patients as it can pick up patients with peripheral neuropathy earlier and so they can be treated earlier.

Among those patients who neither had symptoms nor signs of peripheral neuropathy, 5 patients accepted to undergo nerve conduction study after counseling them and 1 of these 5 patients (20%) showed electrophysiological evidence of peripheral neuropathy. This indicates subclinical neuropathy may be present in 20% of HIV infected patients. However, this is a group of
small number and it has to be evaluated with large number of patients.

Predominant pattern seen was mixed neuropathy (both axonal and demyelination), which was seen in 18 patients. But in literature predominant pattern seen is axonal.\textsuperscript{20,21}

In 13 patients, electrophysiological evidence of peripheral neuropathy was seen in both upper limbs and lower limbs. But clinically many (20/23) had symptoms only in lower limbs. It shows subclinical peripheral neuropathy may be present in upper limbs. Following are the comparison of our study with other studies (Table 6 and 7).\textsuperscript{22,23}

### Table 6: Comparison of our study with other Indian study.

| Factor                                      | Garg J et al\textsuperscript{20} | This study |
|---------------------------------------------|----------------------------------|------------|
| Total no. of patients                      | 39                               | 60         |
| Peripheral Neuropathy present in           | 20                               | 26         |
| Mean duration of HAART (months)            | 24                               | 19         |
| CD4 <200                                    | 17                               | 9          |
| >200                                        | 3                                | 17         |
| Symptoms seen in                           | 20/20 (100%)                     | 23/26 (88%)|
| Signs seen in                              | 20/20 (100%)                     | 25/26 (96%)|
| Electrophysiological evidence of Peripheral Neuropathy seen | 4/20                             | 26/26      |
| Pattern of peripheral neuropathy           | Distal symmetric polyneuropathy. Axonal pattern | Commonly distal symmetric polyneuropathy, others: CIDP, MM. Mixed pattern (both axonal and demyelinating) |
| No. of patients on HAART                   | 17/20                            | 26/26      |
| Correlation between duration of HAART and peripheral neuropathy | No significant relation | less number of peripheral neuropathy patients seen in longer duration of HAART |

### Table 7: Comparison of our study with other international studies.

| Factor                                      | Zanetti C et al\textsuperscript{22} | Gastaut JL et al\textsuperscript{23} | This study |
|---------------------------------------------|-------------------------------------|--------------------------------------|------------|
| Total no. of patients                      | 49                                  | 41                                   | 60         |
| M:F                                         | 32:17                               | -                                    | 33:27      |
| Mean age                                    | 36.8                                | -                                    | 35.6       |
| Age range (years)                          | 21-53                               | -                                    | 21-54      |
| Peripheral Neuropathy seen in              | 34 (69.4%)                          | 36 (88%)                             | 26 (43.3%) |
| Both symptoms and signs seen in            | 12/34                               | -                                    | 23/26      |
| Only signs seen in                         | 22/34                               | -                                    | 2/26       |
| Subclinical (no symptoms, no signs)         | 2                                   | 17                                   | 1/26       |
| Peripheral Neuropathy                      |                                     |                                      |            |
| Neurotoxic drug intake                     | 32 (94.1%)                          | -                                    | 18 (69.2%) |
| Electrophysiological study done in         | 39                                  | -                                    | 30         |
| Peripheral Neuropathy seen in (among those underwent Electrophysiology) | 13/39                             | -                                    | 26/30      |
| Common type seen                           | Distal symmetric polyneuropathy (8/13) | Distal symmetric polyneuropathy      | Distal symmetric polyneuropathy (20/26) |

Some observations of our study go along with other studies.\textsuperscript{24,25} For example the common type, distal symmetric polyneuropathy seen in other studies was also the common type in our study. Prevalence seen in our study (43.3%) was similar to other studies.\textsuperscript{26} In our study, male sex, advanced stage of disease and increasing age were associated with more risk of developing peripheral neuropathy. But these observations were not statistically significant. Only the positive symptom by history and increasing age were significantly associated with the occurrence of peripheral neuropathy. Like other studies CD4 count doesn’t correlate with prevalence of peripheral neuropathy.
CONCLUSION

Several mechanisms might have involved in the pathogenesis of HIV related peripheral neuropathy like neurotoxic effects of the virus and its gene products as well as neurotoxicity of medications used for the treatment of HIV infection. While the diagnosis of HIV related peripheral neuropathy remains largely clinical, other conditions that lead to peripheral neuropathies need to be excluded. Additional research and studies with large number of patients are needed to elucidate the mechanisms leading to peripheral neuropathy in HIV infected patients, which in turn will allow for the development of targeted treatment strategies.

ACKNOWLEDGEMENTS

Authors would like to thank Dr. D. Pethuru, MD (Community Medicine), Assistant Professor, Department of Community Medicine who helped them in analysis of the study results and statistical works. Author also would like to thank all their patients who participated in this study, for their cooperation which made this study possible.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. The Antiretroviral Therapy Cohort Collaboration. Lancet HIV. 2017;4(8):e349-e356.
2. Scott L, Letendre, Ronald J, Ellis, Ivan Everall, Beau Ances, et al. Neurologic Complications of HIV Disease and Their Treatment. Top HIV Med. 2009;17(2):46-56.
3. Mergoel S, Estanisrlo L, Simpson D. HIV-associated distal sensory polyneuropathy in the era of highly active antiretroviral therapy: the Manhattan HIV Brain Bank. Arch Neurol. 2004;61(4):546-51.
4. Shahabuddin S, Badar DS, Moizzuddin KM, Sami LB, Solepure AB. Normative values for nerve conduction study among healthy subjects from Aurangabad, INDIA. IJRTST. 2013;8:56-61.
5. Mallik A, Weir Al. Nerve conduction studies: essentials and pitfalls in practice J Neurology, Neurosurgery Psychiatry. 2005;76:i23-i31.
6. Kimura J. Electrodiagnosis in diseases of nerve and muscle: Principles and Practice. FA Davis, Philadelphia 1986:118.
7. Weinberg JL, Kolvark CL. The WHO clinical staging system for HIV/AIDS. Virtual Mentor. 2010 Mar 1;12(3):202-6.
8. Markarian Y, Wulff EA, Simpson DM. Peripheral neuropathy in HIV disease. AIDS clin care. 1998 Dec;10(12):89-91.
9. Ferrara S, Vento S, Monaco S, Cavallaro T, Cainelli F, Rizzuto N, et al. Human immunodeficiency virus-associated peripheral neuropathies. InMayo Clinic Proceedings 2006 Feb 1 (Vol. 81, No. 2, pp. 213-219). Elsevier.
10. Shankar SK, Mahadevan A, Satishchandra P, Kumar RU, Yasha TC, Santosh V, et al. Neuropathology of HIV/AIDS with an overview of the Indian scene. Indian J Med Res. 2005 Apr 1;121(4):468-88.
11. Tagliati M, Grinnell J, Godbold J, Simpson DM. Peripheral nerve function in HIV infection: clinical, electrophysiologic, and laboratory findings. Archives of neurology. 1999 Jan 1;56(1):84-9.
12. Schifferreno G, McDermott M, McArthur J, Marder K, Sacktor N Epstein L. Incidence of and risk factors for HIV-associated distal sensory polyneuropathy, Neurology. 2002;58(12):1764-8.
13. Wulff EA, Wang AK, Simpson DM. HIV-associated peripheral neuropathy: epidemiology, pathophysiology and treatment. Drugs. 2000;59:1251-60.
14. Luciano CA, Pardo CA, McArthur JC. Recent developments in the HIV neuropathies. Current opinion in neurology, 2003 Jun 1;16(3):403-9.
15. Goodkin K, Wilkie FL, Concha M, Hinkin CH, Symes S, Baldewicz TT, et al. Aging and neuro-AIDS conditions and the changing spectrum of HIV-1-associated morbidity and mortality. J Clinical Epidemiology. 2001;54(12):S35-43.
16. Moyle GJ, Sadler M. Peripheral neuropathy with nucleoside antiretrovirals-risk factors, incidence and management. Drug Safety. 1998;19:481-94.
17. Simpson DM, Tagliati M. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;9:153-61.
18. Fuller GN, Jacobs JM, Guiloff RJ. Nature and incidence of peripheral nerve syndromes in HIV infection. J Neurol Neurosurg Psychiatry. 1993;56:372-81.
19. Hall CD, Snyder CR, Messenheimer JA, Wilkins JW, Robertson WT, Whaley RA, et al. Peripheral neuropathy in a cohort of human immunodeficiency virus-infected patients: Incidence and relationship to other nervous system dysfunction. Archives of neurology. 1991 Dec 1;48(12):1273-4.
20. Garg J, Anand KS, Nath M, Kanwar S. Peripheral neuropathy in HIV infected patients. Annals of Indian Academy of Neurology, 2008;11(2):S133.
21. Fuller GN, Jacobs JM, Guiloff RJ. Subclinical peripheral nerve involvement in AIDS: an electrophysiological and pathological study. J Neurology, Neurosurgery Psychiatry. 1991 Apr 1;54(4):318-24.
22. Zanetti C, Manzano GM, Gabbai AA. The frequency of peripheral neuropathy in a group of
HIV positive patients in Brazil. Arquivos de neuro-psiquiatria. 2004 Jun;62(2A):253-6.

23. Gastaut JL, Gastaut JA, Pellissier JF, Tapko JB, Finaud M, Delpero JR, et al. Neuropathies and HIV retrovirus infections. Revue d'electroencephalo Neurophysiol clin. 1987 Dec;17(4):425-35.

24. Beadles WI, Jahn A, Weigel R, Clutterbuck D. Peripheral neuropathy in HIV-positive patients at an antiretroviral clinic in Lilongwe, Malawi. Trop Doct. 2009 Apr;39(2):78-80.

25. Deshpande AK, Patnaik MM. Nonopportunistic neurologic manifestations of the human immunodeficiency virus: an Indian study. J International AIDS Society. 2005 Dec;7(4):2.

26. Maritz J, Benatar M, Dave JA, Harrison TB, Badri M, Levitt NS, et al. HIV neuropathy in South Africans: frequency, characteristics, and risk factors. Muscle & Nerve: Official J Am Associa Electrodiag Med. 2010 May;41(5):599-606.

Cite this article as: Gunasekaran K, Sivakumar S. A study on peripheral neuropathy in HIV infected patients: clinicoepidemiological and electrophysiological profile. Int J Res Med Sci 2018;6:3226-34.